Determination of 10B in lymphoma human cells after boron carrier treatment: Comparison of 10BPA and immuno-nanoparticles

Marco Giovanni Persico, Patrizia Chiari, Raffaela Biesuz, Giancarla Alberti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Current cancer treatments lead to insufficient distribution of therapeutic agents in tumor cells due to their lack of selectivity often causing adverse effects in the normal cell uptake of the drug. The challenge is to design therapeutic drugs able to maximize the treatment of malignant cancers while minimizing their adverse effects. In this study, 10B incorporation in the B chronic lymphocytic leukemia cell line MEC-1 was investigated. The cells were treated with l-p-10borophenylalanine (10BPA) and 10boron immuno-nanoparticles (BNPs) loaded with 10BPA with or without the anti-CD20 monoclonal antibody for different contact times. The uptake of 10B by the cells was determined by the inductively coupled plasma mass spectrometry (ICP-MS) after acid mineralization. To obtain accurate and consistent data, the analytical procedure was optimized using factorial experimental design. It was observed that BNP loaded with 10BPA and anti-CD20 represents the best carrier system for 10B in B cells for long time (>10 h) whereas 10BPA seems to be the top drug for short time (<4 h) procedures.

Original languageEnglish
Pages (from-to)253-259
Number of pages7
JournalChemical Papers
Volume68
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Boron
Nanoparticles
Lymphoma
Cells
Pharmaceutical Preparations
Inductively coupled plasma mass spectrometry
Monoclonal antibodies
Oncology
Neoplasms
Design of experiments
Tumors
Drug Design
B-Cell Chronic Lymphocytic Leukemia
Monoclonal Antibodies
Mass Spectrometry
Acids
B-Lymphocytes
Research Design
Cell Line
Therapeutics

Keywords

  • boron-10 carrier
  • human tumour cells
  • immuno-nanoparticles
  • in vitro experiments

ASJC Scopus subject areas

  • Chemistry(all)
  • Chemical Engineering(all)
  • Biochemistry
  • Industrial and Manufacturing Engineering
  • Materials Chemistry

Cite this

Determination of 10B in lymphoma human cells after boron carrier treatment : Comparison of 10BPA and immuno-nanoparticles. / Persico, Marco Giovanni; Chiari, Patrizia; Biesuz, Raffaela; Alberti, Giancarla.

In: Chemical Papers, Vol. 68, No. 2, 02.2014, p. 253-259.

Research output: Contribution to journalArticle

Persico, Marco Giovanni ; Chiari, Patrizia ; Biesuz, Raffaela ; Alberti, Giancarla. / Determination of 10B in lymphoma human cells after boron carrier treatment : Comparison of 10BPA and immuno-nanoparticles. In: Chemical Papers. 2014 ; Vol. 68, No. 2. pp. 253-259.
@article{45f7f13ec58644dea5a772b609e79ae3,
title = "Determination of 10B in lymphoma human cells after boron carrier treatment: Comparison of 10BPA and immuno-nanoparticles",
abstract = "Current cancer treatments lead to insufficient distribution of therapeutic agents in tumor cells due to their lack of selectivity often causing adverse effects in the normal cell uptake of the drug. The challenge is to design therapeutic drugs able to maximize the treatment of malignant cancers while minimizing their adverse effects. In this study, 10B incorporation in the B chronic lymphocytic leukemia cell line MEC-1 was investigated. The cells were treated with l-p-10borophenylalanine (10BPA) and 10boron immuno-nanoparticles (BNPs) loaded with 10BPA with or without the anti-CD20 monoclonal antibody for different contact times. The uptake of 10B by the cells was determined by the inductively coupled plasma mass spectrometry (ICP-MS) after acid mineralization. To obtain accurate and consistent data, the analytical procedure was optimized using factorial experimental design. It was observed that BNP loaded with 10BPA and anti-CD20 represents the best carrier system for 10B in B cells for long time (>10 h) whereas 10BPA seems to be the top drug for short time (<4 h) procedures.",
keywords = "boron-10 carrier, human tumour cells, immuno-nanoparticles, in vitro experiments",
author = "Persico, {Marco Giovanni} and Patrizia Chiari and Raffaela Biesuz and Giancarla Alberti",
year = "2014",
month = "2",
doi = "10.2478/s11696-013-0435-4",
language = "English",
volume = "68",
pages = "253--259",
journal = "Chemical Papers",
issn = "0366-6352",
publisher = "Versita",
number = "2",

}

TY - JOUR

T1 - Determination of 10B in lymphoma human cells after boron carrier treatment

T2 - Comparison of 10BPA and immuno-nanoparticles

AU - Persico, Marco Giovanni

AU - Chiari, Patrizia

AU - Biesuz, Raffaela

AU - Alberti, Giancarla

PY - 2014/2

Y1 - 2014/2

N2 - Current cancer treatments lead to insufficient distribution of therapeutic agents in tumor cells due to their lack of selectivity often causing adverse effects in the normal cell uptake of the drug. The challenge is to design therapeutic drugs able to maximize the treatment of malignant cancers while minimizing their adverse effects. In this study, 10B incorporation in the B chronic lymphocytic leukemia cell line MEC-1 was investigated. The cells were treated with l-p-10borophenylalanine (10BPA) and 10boron immuno-nanoparticles (BNPs) loaded with 10BPA with or without the anti-CD20 monoclonal antibody for different contact times. The uptake of 10B by the cells was determined by the inductively coupled plasma mass spectrometry (ICP-MS) after acid mineralization. To obtain accurate and consistent data, the analytical procedure was optimized using factorial experimental design. It was observed that BNP loaded with 10BPA and anti-CD20 represents the best carrier system for 10B in B cells for long time (>10 h) whereas 10BPA seems to be the top drug for short time (<4 h) procedures.

AB - Current cancer treatments lead to insufficient distribution of therapeutic agents in tumor cells due to their lack of selectivity often causing adverse effects in the normal cell uptake of the drug. The challenge is to design therapeutic drugs able to maximize the treatment of malignant cancers while minimizing their adverse effects. In this study, 10B incorporation in the B chronic lymphocytic leukemia cell line MEC-1 was investigated. The cells were treated with l-p-10borophenylalanine (10BPA) and 10boron immuno-nanoparticles (BNPs) loaded with 10BPA with or without the anti-CD20 monoclonal antibody for different contact times. The uptake of 10B by the cells was determined by the inductively coupled plasma mass spectrometry (ICP-MS) after acid mineralization. To obtain accurate and consistent data, the analytical procedure was optimized using factorial experimental design. It was observed that BNP loaded with 10BPA and anti-CD20 represents the best carrier system for 10B in B cells for long time (>10 h) whereas 10BPA seems to be the top drug for short time (<4 h) procedures.

KW - boron-10 carrier

KW - human tumour cells

KW - immuno-nanoparticles

KW - in vitro experiments

UR - http://www.scopus.com/inward/record.url?scp=84890044509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890044509&partnerID=8YFLogxK

U2 - 10.2478/s11696-013-0435-4

DO - 10.2478/s11696-013-0435-4

M3 - Article

AN - SCOPUS:84890044509

VL - 68

SP - 253

EP - 259

JO - Chemical Papers

JF - Chemical Papers

SN - 0366-6352

IS - 2

ER -